erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the..
it's the first successful medical treatment of a human fetus for the underlying cause of a genetic disorder, experts say.